List view / Grid view
9 January 2017 | By Niamh Marriott, Digital Editor
AR-301 (Salvecin) is a fully human monoclonal IgG1 antibody that specifically targets S. aureus alpha-toxin and protects host cells from destruction...
5 January 2017 | By Niamh Marriott, Digital Editor
Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression...
5 January 2017 | By Niamh Marriott, Digital Editor
In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%...
5 January 2017 | By Niamh Marriott (Digital Editor)
Enterome has launched a Phase I clinical study with its lead drug candidate EB8018, a small molecule designed to block FimH, to treat Crohn’s disease...
4 January 2017 | By Niamh Louise Marriott, Digital Editor
Meyenburg joins the company from Alexion Pharmaceuticals, where he most recently served as Senior Vice President of Commercial Operations.
4 January 2017 | By Niamh Louise Marriott, Digital Editor
It is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide...
4 January 2017 | By Niamh Louise Marriott, Digital Editor
The application is based on data from the placebo-controlled Phase III trial which investigated the drug as a second line treatment...
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Preclinical studies suggest GBR 1302 may have activity against a range of HER2-expressing tumour types, including breast, gastric and other cancers...
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Sanofi and its vaccines business unit Sanofi Pasteur will end their vaccine joint-venture with MSD (known as Merck in the US and Canada) - SPMSD...
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in RP...
29 December 2016 | By Niamh Louise Marriott, Digital Editor
Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should...
22 December 2016 | By Niamh Louise Marriott, Digital Editor
Based on the results Orion is planning to apply for a marketing authorisation for the product in Europe. Orion currently estimates that the marketing...
22 December 2016 | By Niamh Louise Marriott, Digital Editor
TiGenix, has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix...
20 December 2016 | By Niamh Louise Marriott, Digital Editor
The National Institute of Health and Care Excellence (NICE) and the United States’ Food and Drug Administration (FDA) will team up, using technology to...
20 December 2016 | By Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release?
